Wedbush Comments on argenx’s FY2026 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Stock analysts at Wedbush cut their FY2026 earnings per share estimates for argenx in a report released on Wednesday, November 20th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $21.65 per share for the year, down from their prior estimate of $22.14. Wedbush currently has a “Outperform” rating and a $560.00 target price on the stock. The consensus estimate for argenx’s current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx’s FY2027 earnings at $34.77 EPS.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company lifted their price objective on argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price for the company in a report on Tuesday, November 12th. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $515.00 to $650.00 in a report on Friday, November 1st. Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and lifted their target price for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft lowered argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $630.42.

argenx Trading Up 1.4 %

Shares of NASDAQ ARGX opened at $600.35 on Friday. argenx has a twelve month low of $327.73 and a twelve month high of $611.22. The stock has a fifty day simple moving average of $555.08 and a 200-day simple moving average of $485.94. The stock has a market capitalization of $35.90 billion, a PE ratio of -682.21 and a beta of 0.61.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the previous year, the firm posted ($1.25) earnings per share.

Institutional Trading of argenx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of argenx by 49.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock valued at $2,167,235,000 after purchasing an additional 1,830,651 shares during the last quarter. FMR LLC lifted its holdings in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of argenx by 0.4% in the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after purchasing an additional 10,975 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of argenx by 0.3% in the 1st quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after purchasing an additional 3,900 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in shares of argenx by 3.6% in the 2nd quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after purchasing an additional 21,189 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.